CG Oncology, Inc Common stock

Yahoo Finance • 4 days ago

CG Oncology Announces New Board Member and Board Transition

- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on d... Full story

Yahoo Finance • 16 days ago

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated continued best-in-disease durability and... Full story

Yahoo Finance • last month

Noteworthy Tuesday Option Activity: CGON, DECK, ARQT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in CG Oncology Inc (Symbol: CGON), where a total of 4,018 contracts have traded so far, representing approximately 401,800 underlying... Full story

Yahoo Finance • 2 months ago

ClearBridge Small Cap Strategy adds KWR, RNA, exits SEAT, GDRX among Q3 moves

The ClearBridge Small Cap Strategy underperformed its Russell 2000 Index benchmark during the third quarter, despite registering gains in 10 of the 11 sectors in which it was invested during the quarter. ClearBridge Small Cap Strategy, in... Full story

Yahoo Finance • 2 months ago

CG Oncology jumps as Guggenheim starts at Buy on potential against bladder cancer

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images CG Oncology (NASDAQ:CGON [https://seekingalpha.com/symbol/CGON]), a biotech focused on non-muscle invasive bladder cancer (NMIBC), traded ~9% higher on Wednesday after G... Full story

Yahoo Finance • 3 months ago

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment - - 90%... Full story

Yahoo Finance • 3 months ago

CG Oncology Completes Enrollment in PIVOT-006

– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) – – One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per... Full story

Yahoo Finance • 3 months ago

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients w... Full story

Yahoo Finance • 3 months ago

Piper Sandler initiates CG Oncology stock coverage with Overweight rating

Investing.com - Piper Sandler initiated coverage on CG Oncology (NASDAQ:CGON) with an Overweight rating and a price target of $55.00 on Tuesday. The company, currently valued at $1.96 billion, trades at $26.13, with analyst targets rangi... Full story

Yahoo Finance • 4 months ago

CG Oncology GAAP EPS of -$0.54

* CG Oncology press release [https://seekingalpha.com/pr/20194834-cg-oncology-reports-second-quarter-2025-financial-results-and-provides-business-updates] (NASDAQ:CGON [https://seekingalpha.com/symbol/CGON]): GAAP EPS of -$0.54. * Cash... Full story

Yahoo Finance • 4 months ago

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Initiated CORE-008 Cohort CX evaluating t... Full story

Yahoo Finance • 5 months ago

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /CNW/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers e... Full story

Yahoo Finance • 6 months ago

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients w... Full story

Yahoo Finance • 7 months ago

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M - - Promising early signal in Cohort P with 90.5% high-grade r... Full story

Yahoo Finance • 7 months ago

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from... Full story

Yahoo Finance • 8 months ago

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Mo... Full story

Yahoo Finance • 9 months ago

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients... Full story

Yahoo Finance • 9 months ago

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients a... Full story